Clinical trial
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery…
NCT00020774 · Jonsson Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00020774 |
|---|---|
| Title | SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer |
| Official title | A Phase IB Clinical Study Of The Farnesyltransferase Inhibitor SCH 66336 And Gemcitabine In Patients With Resectable Primary Liver Neoplasms |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gemcitabine hydrochloride, lonafarnib, conventional surgery |
| Enrollment | 0 |
| Start date | Oct 1, 1998 |
| Primary completion | Jan 1, 2003 |
| First posted | Apr 13, 2004 |
| Last update posted | Jul 31, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: